{
    "clinical_study": {
        "@rank": "1756", 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the safety of DTI-0009 in patients with atrial\n      fibrillation and to find the dose of DTI-0009 that lowers heart rates in patients with\n      atrial fibrillation with rapid ventricular response."
        }, 
        "brief_title": "Safety and Efficacy Study of an A1-Adenosine Receptor Agonist to Slow Heart Rate in Atrial Fibrillation", 
        "condition": "Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Primary diagnosis of atrial fibrillation with rapid ventricular response of any\n             duration as documented by an ECG\n\n        Exclusion Criteria\n\n          -  Presence of other significant cardiac disease or history of significant neurological,\n             hepatic,cardiovascular, renal, gastrointestinal, thyroid, respiratory, rheumatologic,\n             or hematologic disease or impairment that in the investigator\u2019s judgment is serious\n             enough to preclude the patient from safely participating in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "June 18, 2002", 
        "id_info": {
            "nct_id": "NCT00040001", 
            "org_study_id": "DTI-0009/003"
        }, 
        "intervention": {
            "intervention_name": "DTI-0009", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Purinergic P1 Receptor Agonists"
        }, 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Richmond", 
                    "country": "United States", 
                    "state": "Virginia"
                }, 
                "name": "Multiple locations"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00040001"
        }, 
        "source": "Aderis Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aderis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2003"
    }, 
    "geocoordinates": {
        "Multiple locations": "37.541 -77.436"
    }
}